The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 – Novo ...
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...
Pupils from the Blantyre school are among the final four selected for the national Growing Future Assets contest ...
4h
Nvidia has got much-needed ratification after a trio of big tech leaders showed they were unfazed by DeepSeek and disclosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback